Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes

• Hoofdauteurs: G. Tavares (Auteur), D. Marques (Auteur), C. Barra (Auteur), D. Rosendo-Silva (Auteur), A. Costa (Auteur), T. Rodrigues (Auteur), P. Gasparini (Auteur), B.F. Melo (Auteur), J.F. Sacramento (Auteur), R. Seiça (Auteur), S.V. Conde (Auteur), P. Matafome (Auteur)
• Formaat: Boek
• Gepubliceerd in: Elsevier, 2021-09-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Background and objectives: The therapeutic effects of the dopamine D2 receptor (D2R) agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous system actions. However, peripheral dopamine directly modulates glucose uptake in insulin-sensitive tissues and lipid metaboli...